A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma

• Status: Completed
• Trial end date: 2012-05-31
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the preliminary anti-tumor activity and safety profile of a combination of bevacizumab and dacarbazine in participants with unresectable/metastatic melanoma not previously treated with chemotherapy for metastatic disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche
• Treatments: Bevacizumab; Dacarbazine

Criteria

Inclusion Criteria:

• Histologically or cytologically confirmed cutaneous malignant melanoma

• Clinical evidence of metastatic disease and/or unresectable regional lymphatic disease and/or extensive in transit recurrent disease

• Measurable and/or evaluable lesions according to RECIST

Exclusion Criteria:

• Prior interferon alfa and/or cytokine therapy for metastatic disease

• Prior chemotherapy for metastatic disease

• Brain metastases

• Chronic daily treatment with high-dose aspirin (more than 325 milligrams per day)

• Other co-existing malignancies or malignancies diagnosed within the past 5 years with the exception of basal cell cancer or cervical cancer in situ